[
  {
    "ts": null,
    "headline": "Incyte Corp. stock rises Wednesday, still underperforms market",
    "summary": "Incyte Corp. stock rises Wednesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=5b6e910f5e4aa1b434f2ef3f92bc4eb38acdd08b288ecd2628535b9cb8a11d2a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745428560,
      "headline": "Incyte Corp. stock rises Wednesday, still underperforms market",
      "id": 134090942,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock rises Wednesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=5b6e910f5e4aa1b434f2ef3f92bc4eb38acdd08b288ecd2628535b9cb8a11d2a"
    }
  },
  {
    "ts": null,
    "headline": "Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
    "summary": "WILMINGTON, Del., April 23, 2025--Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
    "url": "https://finnhub.io/api/news?id=f36e14f5240ef93823ded2daa0225c93876be492e86b8561b4d2c19336036cb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745420580,
      "headline": "Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
      "id": 134047211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., April 23, 2025--Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
      "url": "https://finnhub.io/api/news?id=f36e14f5240ef93823ded2daa0225c93876be492e86b8561b4d2c19336036cb9"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know",
    "summary": "INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.",
    "url": "https://finnhub.io/api/news?id=b23e4b5106eb22adaf764087de612b5d48a95819e8964d2f1f92f859fc3a9ba1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745409000,
      "headline": "Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know",
      "id": 134047212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.",
      "url": "https://finnhub.io/api/news?id=b23e4b5106eb22adaf764087de612b5d48a95819e8964d2f1f92f859fc3a9ba1"
    }
  }
]